In this article, we will take a look at the 5 stocks to buy with exponential growth. To see more such companies, go directly to 13 Stocks to Buy with Exponential Growth.
5. Sage Therapeutics, Inc. (NASDAQ:SAGE)
Average Sales Growth Over the Past 5 Years: 3190%
Sage Therapeutics, Inc. (NASDAQ:SAGE) was in 26 hedge fund portfolios as of the end of the June quarter, according to Insider Monkey’s database of 910 hedge funds. In August Sage Therapeutics, Inc. (NASDAQ:SAGE) suffered a major setback after the FDA did not give approval to the company’s treatment zuranolone for major depressive disorder. Sage Therapeutics, Inc. (NASDAQ:SAGE) did, however, receive approval for an oral neurosteroid Zurzuvae (Zuranolone) to treat postpartum depression. Sage Therapeutics, Inc. (NASDAQ:SAGE) bulls believe the selloff in August and the overall stock pullback this year is a good buying opportunity for long-term gains. Sage Therapeutics, Inc. (NASDAQ:SAGE)’s revenue jumped 64.8% YoY in the second quarter. At the end of the period it had cash reserves of about $1 billion, and no long-term debt.
4. Prothena Corporation plc (NASDAQ:PRTA)
Average Sales Growth Over the Past 5 Years: 4640%
Prothena Corporation plc (NASDAQ:PRTA) is a late-stage clinical company that is working on treatments for diseases caused by protein dysregulation. Analysts are bullish on Prothena Corporation plc (NASDAQ:PRTA)’s Alzheimer’s pipeline.
In a February earnings call Prothena Corporation plc (NASDAQ:PRTA) talked in detail about its products and pipeline.
“As new data becomes available on the clinical regulatory and commercial landscape in the Alzheimer’s field, we believe our programs are well-positioned to revolutionize the care of patients suffering from this devastating disease. To that end, we can expect the following key milestones in 2023 and 2024. First, preclinical data demonstrating the superior binding characteristics of PRX012 at the upcoming AD/PD 2023 annual meeting. Second, the multiple ascending dose portion of the Phase 1 PRX012 study has commenced, and we are on track to report top line data from the initial cohort by the end of 2023. Third, the Phase 1 multiple ascending dose study for PRX005 is ongoing with top line data expected by year-end 2023, further elucidating the potential of targeting the MTBR tau in treating Alzheimer’s.
Fourth, for PRX123, we are looking forward to submitting an IND by the end of 2023. Fifth, for prasinezumab we expect that Roche will report top line data from the Phase 2b PADOVA study in 2024. Six, in our rare peripheral amyloid portfolio, we continue to …” [read the full earnings call transcript here].
A total of 27 hedge funds out of the 910 hedge funds tracked by Insider Monkey reported owning stakes in Prothena Corporation plc (NASDAQ:PRTA). The most significant stakeholder of Prothena Corporation plc (NASDAQ:PRTA) during this period was Oleg Nodelman’s EcoR1 Capital which owns a $791 million stake in the company.
3. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Average Sales Growth Over the Past 5 Years: 7580%
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares have gained about 13% over the past one year. In August Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted second quarter results. Adjusted EPS in the quarter came in at -$0.45, beating estimates by $0.14. Revenue jumped 99% in the period to $110.8 million, surpassing estimates by $3.99 million.
Insider Monkey’s database of 910 hedge funds shows that 32 hedge funds had stakes in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). The most significant stakeholder of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) was Brandon Haley’s Holocene Advisors which owns an $107 million stake in the company.
2. Mersana Therapeutics, Inc. (NASDAQ:MRSN)
Average Sales Growth Over the Past 5 Years: 12356%
Of the 910 hedge funds in Insider Monkey’s database, 35 hedge funds were long Mersana Therapeutics, Inc. (NASDAQ:MRSN) as of the end of the second quarter of 2023. Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares have plunged this year after the company’s failure to show strong clinical results for Upifitamab rilsodotin (UpRi), an ovarian cancer treatment candidate.
1. CRISPR Therapeutics AG (NASDAQ:CRSP)
Average Sales Growth Over the Past 5 Years: 27206%
CRISPR Therapeutics AG (NASDAQ:CRSP) is perhaps one of the most popular gene editing platform companies. Last month, Mizuho started covering CRISPR Therapeutics AG (NASDAQ:CRSP) with a Buy rating. CRISPR Therapeutics AG (NASDAQ:CRSP) likes the company’s editing platform and its potential to become the next Genentech. Mizuho set an $82 price target on CRISPR Therapeutics AG (NASDAQ:CRSP).
As of the end of the second quarter of 2023, 30 hedge funds tracked by Insider Monkey had stakes in CRISPR Therapeutics AG (NASDAQ:CRSP). The biggest stakeholder of CRISPR Therapeutics AG (NASDAQ:CRSP) during this period was Catherine D. Wood’s ARK Investment Management which owns a $412 million stake in CRISPR Therapeutics AG (NASDAQ:CRSP).
You can also take a peek at 15 Most Innovative Companies in Canada and 15 Best Casino Stocks To Buy Heading Into 2024.
